People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. | — | Biotechnology | Series D+ | $225.9M | $2.2B | 2024 |
| Iterum Therapeutics Ltd | — | Biotechnology | Series C | $131.4M | $115.8M | 2015 |
| CEBIX Inc | — | Pharmaceuticals | Series B | $76.3M | $1.1B | 2009 |
| Amarin Corp Plc\Uk | — | Pharmaceuticals | Series C | $70.0M | $2.5B | 2009 |
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2014 |
| Sorbent Therapeutics Inc | — | Pharmaceuticals | Series B | $58.6M | $221.0M | 2010 |
| Iterum Therapeutics Bermuda Ltd | — | Pharmaceuticals | Series C | $51.6M | $1.8B | 2020 |
James I. Healy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James I. Healy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.